Neurocognitive function in bipolar disorder: A comparison between bipolar I and II disorder and matched controls

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Pålsson, Erik ^a   Figueras, Clara ^a   Johansson, Anette G M ^b   Ekman, Carl Johan ^b   Hultman, Björn ^b   Östlind, Josefin ^a   Landén, Mikael ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; LITHIUM; NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PSYCHOSIS; VERBAL MEMORY; VISUAL MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; BIPOLAR DISORDER; COGNITION; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 84878628780     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-165     Document Type: Article

References (40)

1. Martinez-Aran A, Vieta E, Colom F, Torrent C, Reinares M, Goikolea JM, Benabarre A, Comes M, Sanchez-Moreno J. Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment?. Psychother Psychosom 2005, 74(5):295-302.
2. Tham A, Engelbrektson K, Mathe AA, Johnson L, Olsson E, Aberg-Wistedt A. Impaired neuropsychological performance in euthymic patients with recurring mood disorders. J Clin Psychiatry 1997, 58(1):26-29.
3. Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier IN, Moore PB. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 2006, 93(1-3):105-115.
4. Bauer MS, Calabrese J, Dunner DL, Post R, Whybrow PC, Gyulai L, Tay LK, Younkin SR, Bynum D, Lavori P, et al. Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry 1994, 151(4):506-515.
5. Martinez-Aran A, Vieta E, Colom F, Torrent C, Sanchez-Moreno J, Reinares M, Benabarre A, Goikolea JM, Brugue E, Daban C, et al. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord 2004, 6(3):224-232.
6. Thompson JM, Gallagher P, Hughes JH, Watson S, Gray JM, Ferrier IN, Young AH. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry 2005, 186:32-40.
7. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord 2009, 113(1-2):1-20.
8. Sole B, Martinez-Aran A, Torrent C, Bonnin CM, Reinares M, Popovic D, Sanchez-Moreno J, Vieta E. Are bipolar II patients cognitively impaired? A systematic review. Psychol Med 2011, 41(9):1791-803.
9. Vieta E, Gasto C, Otero A, Nieto E, Vallejo J. Differential features between bipolar I and bipolar II disorder. Compr Psychiatry 1997, 38(2):98-101.
10. Harvey PD, McClure MM, Patterson TL, McGrath JA AEP, Bowie CR, Siever LJ. Impairment in functional capacity as an endophenotype candidate in severe mental illness. Schizophr Bull 2011, 38(6):1318-26.
11. Simonsen C, Sundet K, Vaskinn A, Birkenaes AB, Engh JA, Hansen CF, Jonsdottir H, Ringen PA, Opjordsmoen S, Friis S, et al. Neurocognitive profiles in bipolar I and bipolar II disorder: differences in pattern and magnitude of dysfunction. Bipolar Disord 2008, 10(2):245-255.
12. Torrent C, Martinez-Aran A, Daban C, Sanchez-Moreno J, Comes M, Goikolea JM, Salamero M, Vieta E. Cognitive impairment in bipolar II disorder. Br J Psychiatry 2006, 189:254-259.
13. Dittmann S, Hennig-Fast K, Gerber S, Seemuller F, Riedel M, Emanuel Severus W, Langosch J, Engel RR, Moller HJ, Grunze HC. Cognitive functioning in euthymic bipolar I and bipolar II patients. Bipolar Disord 2008, 10(8):877-887.
14. Chang JS, Choi S, Ha K, Ha TH, Cho HS, Choi JE, Cha B, Moon E. Differential pattern of semantic memory organization between bipolar I and II disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(4):1053-1058.
15. Hsiao YL, Wu YS, Wu JY, Hsu MH, Chen HC, Lee SY, Lee IH, Yeh TL, Yang YK, Ko HC, et al. Neuropsychological functions in patients with bipolar I and bipolar II disorder. Bipolar Disord 2009, 11(5):547-554.
16. Bora E, Yucel M, Pantelis C, Berk M. Meta-analytic review of neurocognition in bipolar II disorder. Acta Psychiatr Scand 2011, 123(3):165-174.
17. Ekman CJ, Lind J, Ryden E, Ingvar M, Landen M. Manic episodes are associated with grey matter volume reduction - a voxel-based morphometry brain analysis. Acta Psychiatr Scand 2010, 122(6):507-515.
18. Ryden E, Johansson C, Blennow K, Landen M. Lower CSF HVA and 5-HIAA in bipolar disorder type 1 with a history of childhood ADHD. J Neural Transm 2009, 116(12):1667-1674.
19. Ryden E, Thase ME, Straht D, Aberg-Wistedt A, Bejerot S, Landen M. A history of childhood attention-deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD. Acta Psychiatr Scand 2009, 120(3):239-246.
20. Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Bio psychiatry 2003, 53(11):1028-1042.
21. Spitzer RL. Psychiatric diagnosis: are clinicians still necessary?. Compr Psychiatry 1983, 24(5):399-411.
22. Guy W. ECDEU Assessment Manual for Psychopharmacology. 1976, 218-222. Rockville, Md: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Department of Health EaW.
23. Luborsky L. Clinician's judgments of mental health. Arch Gen Psychiatry 1962, 7:407-417.
24. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 20(59 Suppl):22. 22-33;quiz 34-57.
25. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol Use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 1993, 88(6):791-804.
26. Berman AH, Bergman H, Palmstierna T, Schlyter F. Evaluation of the drug Use disorders identification test (DUDIT) in criminal justice and detoxification settings and in a swedish population sample. Eur Addict Res 2005, 11(1):22-31.
27. Delis DC, Kaplan E, Kramer JH. Delis-kaplan executive function system (D-KEFS) 2001, San Antonio: The Psychological Corporation.
28. McLaughlin J, Roozendaal B, Dumas T, Gupta A, Ajilore O, Hsieh J, Ho D, Lawrence M, McGaugh JL, Sapolsky R. Sparing of neuronal function postseizure with gene therapy. Proc Natl Acad Sci USA 2000, 97(23):12804-12809.
29. Xu G, Lin K, Rao D, Dang Y, Ouyang H, Guo Y, Ma J, Chen J. Neuropsychological performance in bipolar I, bipolar II and unipolar depression patients: a longitudinal, naturalistic study. J Affect Disord 2012, 136(3):328-339.
30. Arts B, Jabben N, Krabbendam L, van Os J. A 2-year naturalistic study on cognitive functioning in bipolar disorder. Acta Psychiatr Scand 2011, 123(3):190-205.
31. Torrent C, Martinez-Aran A, Daban C, Amann B, Balanza-Martinez V, Del Mar Bonnin C, Cruz N, Franco C, Tabares-Seisdedos R, Vieta E. Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Compr Psychiatry 2011, 52(6):613-22.
32. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000, 57(10):925-935.
33. Tohen M, Waternaux CM, Tsuang MT. Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990, 47(12):1106-1111.
34. Simonsen C, Sundet K, Vaskinn A, Birkenaes AB, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Opjordsmoen S, Melle I, et al. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophr Bull 2011, 37(1):73-83.
35. Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002, 63(2):120-125.
36. Carter TD, Mundo E, Parikh SV, Kennedy JL. Early age at onset as a risk factor for poor outcome of bipolar disorder. J Psychiatr Res 2003, 37(4):297-303.
37. Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL, McElroy SL, Rush AJ, Kupka R, Frye MA, et al. The stanley foundation bipolar treatment outcome network. II. Demographics and illness characteristics of the first 261 patients. J Affect Disord 2001, 67(1-3):45-59.
38. Yusim A, Franklin L, Brooke S, Ajilore O, Sapolsky R. Glucocorticoids exacerbate the deleterious effects of gp120 in hippocampal and cortical explants. J Neurochem 2000, 74(3):1000-1007.
39. Clark L, Iversen SD, Goodwin GM. Sustained attention deficit in bipolar disorder. Br J Psychiatry 2002, 180:313-319.
40. Thompson JM, Gray JM, Hughes JH, Watson S, Young AH, Ferrier IN. Impaired working memory monitoring in euthymic bipolar patients. Bipolar Disord 2007, 9(5):478-489.